Julien Willard

Julien Willard is an American physician and economist. He advises biotech and pharma leaders on strategy, investor relations, and deals. He founded Arcstone Strategy Group, serves as head of research and investments at BioPalace, and lives in San Diego.

Julien Willard in a blue blazer and open-collared white shirt, standing outside a glass-fronted building.

Background

Willard has spent 15 years advising life-sciences leadership. At the World Bank he managed health programs across several governments, including a $500M pandemic response facility. He later led corporate strategy at IBM Life Sciences as a partner, and ran corporate strategy for North America biotech at Accenture Strategy. Before that, he was a health economist at Oxfam GB and represented Oxfam and the UK government as liaison to the UN General Assembly on pharmaceutical access. He published this earlier health-financing work under the name Oleg Kucheryavenko, including World Bank studies on immunization financing and global polio eradication.

He has advised on more than $35 billion in biopharma transactions, including buy-side and sell-side mandates. He led a $1 billion restructuring end to end, covering P&L, workforce, and operating model, and has raised more than $125 million in capital for healthcare and life sciences. He ran operations for a $130 million HIV vaccine program across governments, donors, and research institutions.

Education and credentials

Willard holds an MD from Russian State Medical University in Moscow. He earned an MPH at the London School of Hygiene and Tropical Medicine as a Melinda Gates Scholar, focusing on health economics and pharmaceutical policy. He is a member of the American Economic Association and the International Society for Pharmacoeconomics and Outcomes Research.

Recognition

Willard received the World Bank President’s Award for Excellence and the Melinda Gates Leadership Award.

Current work

Willard founded Arcstone Strategy Group LLC, an advisory practice that serves biopharma C-suites on strategy, transactions, and operations. He serves as head of research and investments at BioPalace. Since June 2026 he has also served as fractional chief operating and financial officer of ThreeO Therapeutics. He hosts Off-Label, a podcast in which biopharma executives debate the industry’s hardest problems across AI, drug discovery, clinical trials, and regulation.

Several of these roles run at the same time. The timeline on the homepage shows how they overlap.

Board service

Willard serves on the boards of Athena and the Southern California Fair Housing Association. He previously sat on the board of the San Diego Youth Symphony, on its finance and audit committee.

Contact

Willard meets clients in San Diego and over Zoom.

If you need a strategist and operator, I would welcome a conversation.